All In Biotech

Drug Trial Radar · NCT07924397

A Study to Assess IG001643 in Healthy Participants

A Randomized, Double-Blinded, Placebo-Controlled, Single- and Multiple-Ascending-Dose Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IG001643 in Healthy Participants

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

86

Planned (sponsor's estimate)

Start

Nov 10, 2026

Primary completion

May 16, 2027

Study completion May 16, 2027

Sponsor

Lead sponsor
Iongen Therapeutics Co., Ltd.Industry
Sponsor type
Industry
First posted
Nov 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IG001643 in Healthy Participants

Conditions

  • Pain Management

Interventions

  • IG001643Drug

    IG001643 oral dosage forms

  • PlaceboDrug

    Placebo for oral dosage forms

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events (TEAEs) with IG001643Time frame: From ICF signing date to Day 15

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • New Zealand Clinical Research

    Christchurch, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.